Rondo Therapeutics

Rondo Therapeutics company information, Employees & Contact Information

At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. We develop innovative bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our bispecific antibodies are designed with broad therapeutic windows, sparing healthy tissue while eradicating tumors. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture.
Looking for a particular Rondo Therapeutics employee's phone or email?

Rondo Therapeutics Questions

News

Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer - Business Wire

Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer Business Wire

Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors - Yahoo Finance

Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors Yahoo Finance

Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors - PR Newswire

Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors PR Newswire

Thomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics’ Bispecific Antibody Programs - Business Wire

Thomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics’ Bispecific Antibody Programs Business Wire

Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer - Business Wire

Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer Business Wire

Rondo Therapeutics to Showcase Next-Generation CD28 Bispecific Platform at Upcoming Therapeutic Antibody Conferences - Business Wire

Rondo Therapeutics to Showcase Next-Generation CD28 Bispecific Platform at Upcoming Therapeutic Antibody Conferences Business Wire

Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics - Business Wire

Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics Business Wire

Top Rondo Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant